isirv Antiviral Group
AVG Home
|
AVG Webinar Series
AVG Webinar series You can listen to the recordings from the AVG webinars which have taken place to date via the links below: 25 October 2022: Treatments/Antiviral Therapeutics - link to the recording 24 January 2023: Antiviral Resistance - link to the recording 20 June 2023: The Present and Future of Treatment Oriented Surveillance - link to the recording 30 Oct 2023: Challenges and Promise of Clinical Trials for Respiratory Antivirals - link to the recording 2024 ISIRV Webinars 24 Jan If you missed the webinar on 24 Jan on 'RSV Vaccination in the Elderly Population' you can register and watch the recording via this link 20 March If you missed this webinar on 'Emerging Influenza and the Human-Animal Interface' you can register and watch the recording via this link 29 May If you missed this webinar on ‘Recent antiviral developments for respiratory viral infections’ you can register and watch the recording via this link 18 June If you missed this webinar on ‘Bovine Influenza and other Hot Topics in Virus Evolution’ you can register and watch the recording via this link
7th AVG Conference (in-person)
We’ve had some great feedback….
AVG Overview
The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More
Latest… Multicountry Spread of Influenza A(H1N1)pdm09 Viruses with Reduced Oseltamivir Inhibition, May 2023-February 2024… read more Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial… read more Discovery of baloxavir sodium as a novel anti-CCHFV inhibitor: Biological evaluation of in vitro and in vivo… read more Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry… read more Spleen tyrosine kinase inhibitor R406 has both antiviral and anti-inflammatory effects on severe influenza A infection… read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA
|
Visit us on:
  Quick links:
Contact AVG:Email:avg@isirv.org |
